Table 3 Multivariate survival analysis for the prognostic value of SPRR1A and ALOX12B in the TCGA final discovery cohort and GEO validation data sets

T stage

T3–4 vs. T1–2

1.17 (0.82–1.67)

0.380

N stage

N2–3 vs. N0–1

1.50 (1.06–2.14)

0.022 *

Age

1.03 (1.01–1.04)

< 0.001 ***

Sex

Male vs. Female

0.84 (0.59–1.20)

0.344

Grade category

G3 vs. G1–2

0.88 (0.61–1.27)

0.486

SPRR1A

0.99 (0.99–1.00)

0.040 *

T stage

T3–4 vs. T1–2

1.92 (1.13–3.26)

0.016 *

N stage

N2–3 vs. N0–1

2.26 (1.38–3.70)

0.001 **

Age

1.03 (1.01–1.05)

0.005**

Sex

Male vs. Female

1.01 (0.55–1.85)

0.972

SPRR1A

0.81 (0.69–0.94)

0.007 **

Cancer stage

Stage III-IV vs. Stage I-II

3.33 (1.68–6.62)

0.001 ***

Age

0.99 (0.97–1.02)

0.726

Sex

Male vs. Female

1.22 (0.67–2.22)

0.511

SPRR1A

0.88 (0.79–0.98)

0.016 *

T stage

T3–4 vs. T1–2

1.13 (0.79–1.60)

0.506

N stage

N2–3 vs. N0–1

1.52 (1.07–2.16)

0.018 *

Age

1.03 (1.01–1.04)

< 0.001 ***

Sex

Male vs. Female

0.84 (0.59–1.20)

0.335

Grade category

G3 vs. G1–2

0.90 (0.63–1.29)

0.561

ALOX12B

0.99 (0.98–0.99)

0.034 *

T stage

T3–4 vs. T1–2

1.93 (1.13–3.29)

0.016 *

N stage

N2–3 vs. N0–1

2.16 (1.32–3.55)

0.002 **

Age

1.03 (1.01–1.06)

0.002**

Sex

Male vs. Female

1.12 (0.62–2.05)

0.707

ALOX12B

0.76 (0.59–0.98)

0.032 *

Cancer stage

Stage III-IV vs. Stage I-II

3.52 (1.78–6.96)

< 0.001 ***

Age

0.99 (0.97–1.02)

0.895

Sex

Male vs. Female

1.20 (0.66–2.20)

0.555

ALOX12B

0.93 (0.83–1.04)

0.209